Patient perceptions concerning clinical trials in oncology patients
نویسندگان
چکیده
منابع مشابه
Patient decision making concerning clinical trials.
Note: This column is made possible through an educational grant from CChange, a Washington, DC, based organization comprising the nation’s key cancer leaders from government, business, and nonprofit sectors. These cancer leaders share the vision of a future where cancer is prevented, detected early, and cured or is managed successfully as a chronic illness. The mission of C-Change is to leverag...
متن کاملClinical Trials in Paediatric Oncology
Childhood and adolescent cancers are rare diseases. Despite the progress in treatment (more than two-thirds of all cases are cured), cancer remains the leading cause of death by disease in children older than 1 year. Access to new drugs that are more efficacious or better tolerated is therefore an important public health priority. The objective of our round table was thus to take inventory of t...
متن کاملA Review on Medicinal Plants Used in Animal Models and Clinical Trials concerning Drug Addiction
Addiction to drugs, such as heroin, cocaine and alcohol, exacts great human and financial costs on society. Various evidence-based pharmacological and psychosocial interventions are currently used in the treatment of drug addiction but they do not produce adequate therapeutic benefits in every patient. Further, barriers such as financial cost, lack of availability, or perceptions of existing tr...
متن کاملPatients' perceptions of information provided in clinical trials.
BACKGROUND According to the Declaration of Helsinki, patients who take part in a clinical trial must be adequately informed about the trial's aims, methods, expected benefits, and potential risks. The declaration does not, however, elaborate on what "adequately informed" might amount to, in practice. Medical researchers and Local Research Ethics Committees attempt to ensure that the information...
متن کاملClinical Trials in Oncology and Defining Benefit
In the editorial “The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs” [1], Goldberg et al. nicely discuss many changing aspects of clinical trial design in oncology. However, I believe their title is misleading. No study will define “who benefits” but only who might benefit. For example, human epidermal growth receptor 2 overexpress...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Contemporary Clinical Trials Communications
سال: 2016
ISSN: 2451-8654
DOI: 10.1016/j.conctc.2016.09.005